In recent trading session, Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) saw 1,844,708 shares changing hands with its beta currently measuring 2. Company’s recent per share price level of $8.43 trading at $1.57 or 22.89% at recent trade assigns it a market valuation of $305.97 Million. That current trading price of ALDX’s stock is at a discount of -0.71% from its 52-week high price of $8.49 and is indicating a premium of 82.44% from its 52-week low price of $1.48. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 256.05 Million shares which gives us an average trading volume of 736.03 Million if we extend that period to 3-months.

For Aldeyra Therapeutics, Inc. (ALDX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.6. Splitting up the data highlights that, out of 6 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. None suggested the stock as a Hold whereas 6 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.28 in the current quarter.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) trade information

Upright in the green today for gaining 22.89%, in the last five days ALDX remained trading in the green while hitting it’s week-highest on Friday, Oct 16 when the stock touched $8.20-0 price level, adding 0.47% to its value on the day. Aldeyra Therapeutics, Inc.’s shares saw a change of 40.47% in year-to-date performance and have moved 15.76% in past 5-day. Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) showed a performance of 14.78% in past 30-days. Number of shares sold short was 1.7 Million shares which calculate 0 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of $26.83 to the stock, which implies a rise of 218.27% to its current value. Analysts have been projecting $15 as a low price target for the stock while placing it at a high target of $33. It follows that stock’s current price would jump +291.46% in reaching the projected high whereas dropping to the targeted low would mean a loss of 77.94% for stock’s current value.

Aldeyra Therapeutics, Inc. (ALDX) estimates and forecasts

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 2.2% during past 5 years. In 2020, company’s earnings growth rate is likely to be around -25.1% while estimates for its earnings growth in next 5 years are of 0%

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)’s Major holders

Insiders are in possession of 4.01% of company’s total shares while institution are holding 65.87% percent of that, with stock having share float percentage of 68.63%. Investors also watch the number of corporate investors in a company very closely, which is 109 institutions for Aldeyra Therapeutics, Inc. that are currently holding shares of the company. Perceptive Advisors Llc is the top institutional holder at ALDX for having 3.09 Million shares of worth $12.87 Million. And as of June 29, 2020, it was holding 7.99% of the company’s outstanding shares.

The second largest institutional holder is Prosight Management, LP, which was holding about 1.62 Million shares on June 29, 2020. The number of shares represents firm’s hold over 4.19% of outstanding shares, having a total worth of $6.76 Million.

On the other hand, Vanguard Total Stock Market Index Fund and Fidelity Select Portfolios – Biotechnology are the top two Mutual Funds which own company’s shares. As of June 29, 2020, the former fund manager was holding 667217 shares of worth $2.78 Million or 1.73% of the total outstanding shares. The later fund manager was in possession of 446.93 Thousand shares on July 30, 2020, making its stake of worth around $2.87 Million in the company or a holder of 1.16% of company’s stock.